ID   600MPE
AC   CVCL_9875
AS   CVCL_8287
SY   600 MPE; 600-MPE; MPE-600; MPE 600; MPE600; 600PE; 600-PEI
DR   CLO; CLO_0009908
DR   EFO; EFO_0001085
DR   ArrayExpress; E-TABM-157
DR   ArrayExpress; E-TABM-244
DR   cancercelllines; CVCL_9875
DR   Cosmic; 997932
DR   Cosmic; 1000128
DR   Cosmic; 1046948
DR   Cosmic; 1091346
DR   Cosmic; 1136351
DR   Cosmic; 1176628
DR   Cosmic; 1287907
DR   Cosmic; 1289403
DR   Cosmic; 2301521
DR   DepMap; ACH-002320
DR   GEO; GSM814
DR   GEO; GSM320174
DR   GEO; GSM421881
DR   GEO; GSM1053688
DR   GEO; GSM1172938
DR   GEO; GSM1172850
DR   GEO; GSM1661985
DR   IARC_TP53; 24335
DR   LINCS_HMS; 51092
DR   LINCS_LDP; LCL-2073
DR   PharmacoDB; 600MPE_22_2019
DR   Progenetix; CVCL_9875
DR   Wikidata; Q54604225
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   PubMed=3470538;
RX   PubMed=10862037;
RX   PubMed=10969801;
RX   PubMed=11687795;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=17157791;
RX   PubMed=18516279;
RX   PubMed=19593635;
RX   PubMed=23601657;
RX   PubMed=24094812;
RX   PubMed=24176112;
RX   PubMed=25960936;
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: GrayJW breast cancer cell line panel.
CC   Doubling time: 85.17 hours (GrayJW panel).
CC   HLA typing: A*29:02,29:02; B*44:02,44:02; C*16:02,16:02 (PubMed=25960936).
CC   Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; c.1138-21_1138del22; Zygosity=Homozygous (PubMed=19593635).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=19593635).
CC   Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; c.219-1G>C; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=19593635).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: MPE699; Cosmic=1287907.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   46Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 32
//
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RA   Leibovitz A.;
RT   "Cell lines from human breast.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994).
//
RX   PubMed=3470538; DOI=10.1093/jnci/78.4.611;
RA   Smith H.S., Wolman S.R., Dairkee S.H., Hancock M.C., Lippman M.E.,
RA   Leff A., Hackett A.J.;
RT   "Immortalization in culture: occurrence at a late stage in the
RT   progression of breast cancer.";
RL   J. Natl. Cancer Inst. 78:611-615(1987).
//
RX   PubMed=10862037; DOI=10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B;
RA   Kytola S., Rummukainen J., Nordgren A., Karhu R., Farnebo F.,
RA   Isola J., Larsson C.;
RT   "Chromosomal alterations in 15 breast cancer cell lines by comparative
RT   genomic hybridization and spectral karyotyping.";
RL   Genes Chromosomes Cancer 28:308-317(2000).
//
RX   PubMed=10969801;
RA   Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y.,
RA   Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.;
RT   "Comparative genomic hybridization analysis of 38 breast cancer cell
RT   lines: a basis for interpreting complementary DNA microarray data.";
RL   Cancer Res. 60:4519-4525(2000).
//
RX   PubMed=11687795; DOI=10.1038/ng754;
RA   Snijders A.M., Nowak N.J., Segraves R., Blackwood S., Brown N.,
RA   Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S.,
RA   Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N.,
RA   Pinkel D., Albertson D.G.;
RT   "Assembly of microarrays for genome-wide measurement of DNA copy
RT   number.";
RL   Nat. Genet. 29:263-264(2001).
//
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
//
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
//
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
//
RX   PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004;
RA   Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R.,
RA   Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H.,
RA   Petersen O.W., Gray J.W., Bissell M.J.;
RT   "The morphologies of breast cancer cell lines in three-dimensional
RT   assays correlate with their profiles of gene expression.";
RL   Mol. Oncol. 1:84-96(2007).
//
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G.,
RA   den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
//
RX   PubMed=23601657; DOI=10.1186/bcr3415;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33.1-R33.17(2013).
//
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//